Cargando…

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

Detalles Bibliográficos
Autores principales:	Miller, Bradley S, Blair, Joanne C, Rasmussen, Michael Højby, Maniatis, Aristides, Kildemoes, Rasmus Juul, Mori, Jun, Polak, Michel, Bang, Rikke Beck, Böttcher, Volker, Stagi, Stefano, Horikawa, Reiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Invited Letter to the Editor Response
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348454/ https://www.ncbi.nlm.nih.gov/pubmed/36869702 http://dx.doi.org/10.1210/clinem/dgad095

Ejemplares similares

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4
por: Blair, Joanne, et al.
Publicado: (2023)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Chatelain, Pierre, et al.
Publicado: (2023)

RF26 | PMON335 Once-Weekly Somapacitan Versus Daily Growth Hormone in Children Born Small for Gestational Age: Results From a Randomized Phase 2 Trial
por: Juul, Anders, et al.
Publicado: (2022)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants
por: Rasmussen, Michael Højby, et al.
Publicado: (2023)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials
por: Juul, Rasmus Vestergaard, et al.
Publicado: (2018)

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial
por: Savendahl, Lars, et al.
Publicado: (2022)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

OR21-01 Pre-treatment Blood Transcriptome Predicts First-year Growth And IGF-I Response To Somapacitan Treatment In Children With GH Deficiency
por: Garner, Terence, et al.
Publicado: (2023)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Letter to the Editor
por: Tolstrup Larsen, Rasmus
Publicado: (2018)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
por: Bentz Damholt, Birgitte, et al.
Publicado: (2021)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Letter to the editor response
por: Krawiec, Conrad, et al.
Publicado: (2022)

Corrigendum to: “Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial”
Publicado: (2020)

Correction to: “Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH”
Publicado: (2023)

Letter to the Editor Response Regarding “Research Equity in Otolaryngology–Head and Neck Surgery”
por: Patterson, Rolvix Harlan, et al.
Publicado: (2021)

Response to: "Letter to the Editor– Observation on the article titled “Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India”"
por: John, Christy V., et al.
Publicado: (2023)

Response to Letter to the Editor From Virú-Loza and Chávez-Nomberto: “Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort”
por: Maghnie, Mohamad, et al.
Publicado: (2023)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

Letter to the Editor: Response
por: Aune, Kyle T., et al.
Publicado: (2018)

Response to Letter to the Editor entitled “Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor Like1-Positive Membranous Nephropathy”
por: Ueda, Hiroyuki
Publicado: (2023)

Letter to the Editor: Authors' Response
por: Cetin, Mehtap Bilgin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orh5vmj8rs24aeiea6hoj1v7k7